Prothena Corporation Plc (PRTA)

$20.57

-0.43

(-2.05%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Prothena Corporation Plc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 84.86M → 316.0K (in $), with an average decrease of 99.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 21.90M → -67.47M (in $), with an average decrease of 408.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 107.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 260.6%

Performance

  • $20.47
    $21.23
    $20.57
    downward going graph

    0.49%

    Downside

    Day's Volatility :3.56%

    Upside

    3.09%

    downward going graph
  • $20.57
    $79.65
    $20.57
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :74.17%

    Upside

    74.17%

    downward going graph

Returns

PeriodProthena Corporation PlcSector (Health Care)Index (Russel 2000)
3 Months
-35.02%
-0.7%
0.0%
6 Months
-53.24%
6.6%
0.0%
1 Year
-60.47%
3.7%
-1.5%
3 Years
-11.62%
14.0%
-21.8%

Highlights

Market Capitalization
1.2B
Book Value
$10.46
Earnings Per Share (EPS)
-2.76
PEG Ratio
0.8
Wall Street Target Price
66.77
Profit Margin
-160.91%
Operating Margin TTM
-24846.52%
Return On Assets TTM
-16.42%
Return On Equity TTM
-24.85%
Revenue TTM
91.4M
Revenue Per Share TTM
1.72
Quarterly Revenue Growth YOY
-99.4%
Gross Profit TTM
-81.7M
EBITDA
-190.1M
Diluted Eps TTM
-2.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.86
EPS Estimate Next Year
-4.13
EPS Estimate Current Quarter
-1.22
EPS Estimate Next Quarter
-1.34

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Prothena Corporation Plc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
14
Hold
3
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 224.6%

Current $20.57
Target $66.77

Company Financials

FY18Y/Y Change
Revenue
955.0K
↓ 96.53%
Net Income
-155.6M
↑ 1.57%
Net Profit Margin
-16.3K%
↓ 15741.07%
FY19Y/Y Change
Revenue
814.0K
↓ 14.76%
Net Income
-77.7M
↓ 50.09%
Net Profit Margin
-9.5K%
↑ 6755.28%
FY20Y/Y Change
Revenue
853.0K
↑ 4.79%
Net Income
-111.1M
↑ 43.08%
Net Profit Margin
-13.0K%
↓ 3487.15%
FY21Y/Y Change
Revenue
200.6M
↑ 23414.3%
Net Income
67.0M
↓ 160.26%
Net Profit Margin
33.39%
↑ 13063.17%
FY22Y/Y Change
Revenue
53.9M
↓ 73.13%
Net Income
-116.9M
↓ 274.62%
Net Profit Margin
-216.95%
↓ 250.34%
FY23Y/Y Change
Revenue
91.4M
↑ 69.5%
Net Income
-147.0M
↑ 25.72%
Net Profit Margin
-160.91%
↑ 56.04%
Q3 FY22Q/Q Change
Revenue
1.5M
↑ 15.63%
Net Income
-45.8M
↑ 10.96%
Net Profit Margin
-3.0K%
↑ 126.86%
Q4 FY22Q/Q Change
Revenue
49.9M
↑ 3190.9%
Net Income
6.3M
↓ 113.87%
Net Profit Margin
12.72%
↑ 3029.46%
Q1 FY23Q/Q Change
Revenue
2.2M
↓ 95.66%
Net Income
-46.9M
↓ 838.13%
Net Profit Margin
-2.2K%
↓ 2173.35%
Q2 FY23Q/Q Change
Revenue
4.0M
↑ 85.29%
Net Income
-54.6M
↑ 16.5%
Net Profit Margin
-1.4K%
↑ 802.21%
Q3 FY23Q/Q Change
Revenue
84.9M
↑ 2011.62%
Net Income
21.9M
↓ 140.13%
Net Profit Margin
25.81%
↑ 1384.23%
Q4 FY23Q/Q Change
Revenue
316.0K
↓ 99.63%
Net Income
-67.5M
↓ 408.01%
Net Profit Margin
-21.4K%
↓ 21378.97%
FY18Y/Y Change
Total Assets
498.8M
↑ 0.5%
Total Liabilities
175.8M
↑ 97.22%
FY19Y/Y Change
Total Assets
419.3M
↓ 15.94%
Total Liabilities
146.3M
↓ 16.75%
FY20Y/Y Change
Total Assets
333.0M
↓ 20.58%
Total Liabilities
149.0M
↑ 1.79%
FY21Y/Y Change
Total Assets
609.4M
↑ 83.01%
Total Liabilities
143.3M
↓ 3.79%
FY22Y/Y Change
Total Assets
758.0M
↑ 24.4%
Total Liabilities
136.0M
↓ 5.11%
FY23Y/Y Change
Total Assets
696.4M
↓ 8.13%
Total Liabilities
135.0M
↓ 0.72%
Q3 FY22Q/Q Change
Total Assets
554.4M
↑ 0.88%
Total Liabilities
149.8M
↑ 5.27%
Q4 FY22Q/Q Change
Total Assets
758.0M
↑ 36.72%
Total Liabilities
136.0M
↓ 9.21%
Q1 FY23Q/Q Change
Total Assets
741.6M
↓ 2.17%
Total Liabilities
134.2M
↓ 1.34%
Q2 FY23Q/Q Change
Total Assets
720.6M
↓ 2.82%
Total Liabilities
139.0M
↑ 3.57%
Q3 FY23Q/Q Change
Total Assets
746.9M
↑ 3.65%
Total Liabilities
129.7M
↓ 6.68%
Q4 FY23Q/Q Change
Total Assets
696.4M
↓ 6.77%
Total Liabilities
135.0M
↑ 4.11%
FY18Y/Y Change
Operating Cash Flow
-28.3M
↓ 78.45%
Investing Cash Flow
-1.7M
↓ 50.89%
Financing Cash Flow
40.0M
↓ 75.79%
FY19Y/Y Change
Operating Cash Flow
-53.0M
↑ 87.33%
Investing Cash Flow
-547.0K
↓ 68.36%
Financing Cash Flow
228.0K
↓ 99.43%
FY20Y/Y Change
Operating Cash Flow
-80.4M
↑ 51.72%
Investing Cash Flow
-196.0K
↓ 64.17%
Financing Cash Flow
215.0K
↓ 5.7%
FY21Y/Y Change
Operating Cash Flow
92.6M
↓ 215.23%
Investing Cash Flow
-575.0K
↑ 193.37%
Financing Cash Flow
190.3M
↑ 88426.51%
FY22Y/Y Change
Operating Cash Flow
-108.8M
↓ 217.51%
Investing Cash Flow
-464.0K
↓ 19.3%
Financing Cash Flow
241.5M
↑ 26.86%
Q3 FY22Q/Q Change
Operating Cash Flow
-31.2M
↓ 11.62%
Investing Cash Flow
-130.0K
↓ 19.25%
Financing Cash Flow
18.1M
↑ 1380.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.0M
↓ 84.03%
Investing Cash Flow
-151.0K
↑ 16.15%
Financing Cash Flow
220.8M
↑ 1117.68%
Q1 FY23Q/Q Change
Operating Cash Flow
-47.5M
↑ 853.74%
Investing Cash Flow
-48.0K
↓ 68.21%
Financing Cash Flow
23.3M
↓ 89.45%
Q2 FY23Q/Q Change
Operating Cash Flow
-44.9M
↓ 5.33%
Investing Cash Flow
-771.0K
↑ 1506.25%
Financing Cash Flow
18.6M
↓ 20.01%
Q3 FY23Q/Q Change
Operating Cash Flow
9.5M
↓ 121.18%
Investing Cash Flow
-442.0K
↓ 42.67%
Financing Cash Flow
2.7M
↓ 85.44%

Technicals Summary

Sell

Neutral

Buy

Prothena Corporation Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prothena Corporation Plc
Prothena Corporation Plc
-16.3%
-53.24%
-60.47%
-11.62%
96.26%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prothena Corporation Plc
Prothena Corporation Plc
35.44
NA
0.8
-4.86
-0.25
-0.16
NA
10.46
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prothena Corporation Plc
Prothena Corporation Plc
Buy
$1.2B
96.26%
35.44
-160.91%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • EcoR1 Capital, LLC

    21.56%

  • FMR Inc

    14.98%

  • T. Rowe Price Associates, Inc.

    7.89%

  • BlackRock Inc

    7.02%

  • State Street Corporation

    5.14%

  • Wellington Management Company LLP

    4.83%

Company Information

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f

Organization
Prothena Corporation Plc
Employees
173
CEO
Dr. Gene G. Kinney Ph.D.
Industry
Health Technology

Discover More

FAQs